Indica vs sativa: what the science actually says

Indica and sativa labels do not predict how a product will make you feel. That is not a contrarian opinion; it is what the genomic and chemical evidence shows.

A 2021 study in Nature Plants analysed over 100 cannabis samples, quantified for terpene and cannabinoid content and genotyped at more than 100,000 single nucleotide polymorphisms. The finding, in the authors' words: sativa- and indica-labelled samples "were genetically indistinct on a genome-wide scale."

The first ten genetic principal components explained only 37% of labelling variance. What labelling did track was a small number of terpenes controlled by tandem arrays of terpene synthase genes — with myrcene alone accounting for about 21% of indica labelling.

A 2022 PLOS ONE analysis went considerably larger: 89,923 commercial flower samples across six US states, 42,843 with complete terpene data. Indica, hybrid, and sativa categories were "highly intermingled" with no obvious chemical segregation, and most samples had negative silhouette scores — a statistical way of saying the labels do not describe real clusters.

What the data did show was three genuine terpene chemotypes among THC-dominant samples, and all three cut across the indica/sativa labels: high beta-caryophyllene with limonene; high myrcene with pinene; and high terpinolene with myrcene.

Researchers prefer "chemovar" — chemical variety. The practical version: when something works for you, write down the total THC, the total CBD, and the top three terpenes from the batch lab result.

That combination is reproducible across growers and product names in a way that "Northern Lights" is not.

Even a terpene profile has not been shown in controlled human trials to predict effects. It is a better label than indica or sativa because it describes real, measured chemistry — but the link from chemistry to experience is still largely unmapped.